Physician profile
Ralph Palumbo
NPI 1295717718
$6,167.94
in general payments reported to CMS, 2019-2025
34 companies · $2,051 in 2025
The $2,051 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,964 · 2020: $366 · 2021: $30.65 · 2022: $15.23 · 2023: $26.52 · 2024: $714 · 2025: $2,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.84 |
| Education | $279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,053.37 | 2019-2025 | Fasenra, Tagrisso, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.44 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $488.29 | 2019-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $436.15 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $367.49 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $290.00 | 2025 | Ohtuvayre |
| Insmed, INC. | $284.16 | 2022-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $193.24 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $137.54 | 2019-2025 | Dupixent |
| Genzyme Corporation | $126.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $111.94 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $100.41 | 2019-2020 | |
| Grifols USA, LLC | $98.89 | 2019-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $95.25 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $94.82 | 2019-2025 | Zerbaxa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $87.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.63 | 2024-2025 | Hyqvia, Glassia |
| Genentech USA, INC. | $56.57 | 2019 | |
| Ani Pharmaceuticals, INC. | $54.69 | 2024-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $53.66 | 2019-2025 | |
| Inspire Medical Systems, INC. | $47.64 | 2025 | Inspire |
| La Jolla Pharmaceutical Company | $46.18 | 2019-2020 | |
| Csl Behring | $41.47 | 2019 | |
| United Therapeutics Corporation | $39.04 | 2021-2024 | Tyvaso |
| Lilly USA, LLC | $38.70 | 2025 | Zepbound |
| Electromed, INC. | $36.08 | 2019-2025 | Smartvest |
| Fisher & Paykel Healthcare INC | $29.64 | 2024 | Fisher & Paykel Healthcare |
| Pfizer INC. | $26.92 | 2019 | |
| Shionogi INC | $26.52 | 2023 | Fetroja |
| Baxter Healthcare | $22.42 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Advanced Respiratory, INC | $17.44 | 2020 | |
| Allergan, INC. | $15.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.03 | 2020 | |
| Philips North America LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Palumbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.